1. Molecular imaging with nanoparticles: the dwarf actors revisited 10 years later
- Author
-
Gudrun C. Thurner and Paul Debbage
- Subjects
Translation ,Histology ,Computer science ,Near infrared ,02 engineering and technology ,Review ,010402 general chemistry ,01 natural sciences ,Nanotechnology ,Quantum nanoparticles ,Animals ,Humans ,Molecular Biology ,Targeting ,Low toxicity ,Tunable photoluminescence ,Cell Biology ,021001 nanoscience & nanotechnology ,Data science ,0104 chemical sciences ,Molecular Imaging ,Medical Laboratory Technology ,Nanomedicine ,Nanoparticles ,0210 nano-technology - Abstract
We explore present-day trends and challenges in nanomedicine. Creativity in the laboratories continues: the published literature on novel nanoparticles is now vast. Nanoagents are discussed here which are composed entirely of strongly photoluminescent materials, tunable to desired optical properties and of inherently low toxicity. We focus on “quantum nanoparticles” prepared from allotropes of carbon. The principles behind strong, tunable photoluminescence are quantum mechanical: we present them in simple outline. The major industries racing to develop these materials can offer significant technical guidance to nanomedicine, which could help to custom-design strongly signalling nanoagents specifically for stated clinical applications. Since such agents are small, they can be targeted easily, making active targeting possible. We consider it timely now to study the interactions nanoparticles undergo with tissue components in living animals and to learn to understand and overcome the numerous barriers the organism interposes between the blood and targets in or on parenchymal cells. As the near infra-red spectrum opens up, detection of glowing nanoparticles several centimeters deep in a living human subject becomes calculable and we present a simple way to do this. Finally, we discuss the slow-fuse and resource-inefficient entry of nanoparticles into clinical application. A first possible reason is failure to target across the body’s barriers, see above. Second, in the sparse translational landscape funding and support gaps yawn widely between academic research and subsequent development. We consider the agendas of the numerous “stakeholders” participating in this sad landscape and point to some faint glimmers of hope for the future.
- Published
- 2018